JNJ 109.01 Johnson & Johnson $JNJ Hit a 52 week hi

JNJ 109.01 Johnson & Johnson $JNJ Hit a 52 week high of 109.32 Closing the day 11/06/14 at 109.01 +0.19 +0.17% With a day low of 108.55 and a total volume of 6,200,362.

JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/

JNJ Johnson & Johnson Recent Headline News

Final Glance: Pharmaceuticals companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)

Final Glance: Medical Devices companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.19 (-0.80), JNJ: 109.01 (+0.19), MDT: 68.74 (+0.04), BAX: 71.60 (+0.70)

J&J Snack Foods posts 4Q profit
Automated Insights - Thu Nov 06, 4:48PM CST
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Thursday reported profit of $22.2 million, or $1.19 per share, in its fiscal fourth quarter.
JNJ: 109.01 (+0.19), JJSF: 103.75 (+0.76)

Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting
Marketwired - Thu Nov 06, 3:20PM CST
Alios BioPharma, Inc., announced the upcoming presentation of preclinical data from two of its anti-hepatitis C virus (HCV) nucleotide analogs at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) beginning tomorrow in Boston. Data from two novel compounds -- AL-335, a potent uridine based nucleotide analog and AL-516, a potent guanosine based nucleotide analog -- will be presented in two poster sessions on Tuesday, November 11.
JNJ: 109.01 (+0.19)

Midday Glance: Pharmaceuticals companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)

Midday Glance: Medical Devices companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.19 (-0.80), JNJ: 109.01 (+0.19), MDT: 68.74 (+0.04), BAX: 71.60 (+0.70)

Early Glance: Pharmaceuticals companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)

Early Glance: Medical Devices companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.19 (-0.80), JNJ: 109.01 (+0.19), MDT: 68.74 (+0.04), BAX: 71.60 (+0.70)

Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 109.01 (+0.19), PCYC: 137.12 (+6.09), AZN: 72.85 (-0.62), AMAG: 34.12 (+0.34)

DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50
ACCESSWIRE - Wed Nov 05, 8:26AM CST
900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA
JNJ: 109.01 (+0.19)

Johnson & Johnson Considering Settlement of $250 Million to Close More Than 1,000 DePuy ASR Metal-on-Metal Hip Device Claims, Parker Waichman LLP Comments.
PRWeb - Wed Nov 05, 8:07AM CST
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that healthcare giant, Johnson & Johnson, may settle for more than $250 million to resolve lawsuits that were brought over its DePuy Orthopaedics unit's ASR (articular surface replacements) metal-on-metal hip implant devices. The potential settlement involves cases that were not included in a 2013 settlement of $2.5 billion that involved similar device failure claims, according to an October 13, 2014 Bloomberg News report. The consolidated federal case is: In re DePuy Orthopedics Inc., ASR Hip Implant Products Liability Litigation, 10-MD-2197, U.S. District Court, Northern District of Ohio (Toledo).
JNJ: 109.01 (+0.19)

After Yesterday's Rally of 1.08% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:42PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $107.34 to a high of $108.73. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.18 on volume of 9.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 109.01 (+0.19)

Johnson & Johnson Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Tue Nov 04, 3:41PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $107.34 to a high of $108.73. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.18 on volume of 9.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 109.01 (+0.19)

Baron and Budd Investigating Potential Xarelto Lawsuits
Business Wire - Tue Nov 04, 3:01PM CST
The attorneys at the national law firm of Baron and Budd have been investigating potential lawsuits involving the blood thinner Xarelto, a prescription drug distributed in the United States by Johnson & Johnson subsidiary Janssen Pharmaceuticals. Several patients have reported serious health problems after using the drug, including blood clots, strokes, kidney and liver damage, and severe internal bleeding - a sometimes fatal condition.
JNJ: 109.01 (+0.19)